Sample-targeted clinical trial adaptation

Proceedings of the National Conference on Artificial Intelligence

Volumn 3, Issue , 2015, Pages 1693-1699

  Arandjelović, Ognjen ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PATIENT TREATMENT;

AUXILIARY DATA; CLINICAL TRIAL; ITS APPLICATIONS; MEDICAL INTERVENTION; SAMPLE SIZES; SUB-GROUPS;

ARTIFICIAL INTELLIGENCE;

EID: 84959904171     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (27)

1. Aitchison, J., and Brown, J. A. C. 1957. The Lognormal Distribution. Cambridge University Press.
2. Arandjelovic, O. 2012a. Assessing blinding in clinical trials. Advances in Neural Information Processing Systems (NIPS) 25:530-538.
3. Arandjelovic, O. 2012b. A new framework for interpreting the outcomes of imperfectly blinded controlled clinical trials. PLOS ONE 7(12):e48984.
4. Bang, H.; Ni, L.; and Davis, C. E. 2004. Assessment of blinding in clinical trials. Contemp Clin Trials 25(2): 143-156.
5. Berger, V. 2005. Selection Bias and Covariate Imbalances in Randomized Clinical Trials. Hoboken, New Jersey: Wiley.
6. Bhattacharyya, A. 1943. On a measure of divergence between two statistical populations defined by their probability distributions. Bulletin of the Calcutta Mathematical Society 35:99-109.
7. Chow, S.-C, and Chan, M. 2011. Adaptive Design Methods in Clinical Trials. Chapman & Hall.
8. Cui, L.; Hung, H. M. J.; and Wang, S. J. 1999. Modification of sample size in group sequential clinical trials. Biometrics 55:321-324.
9. Fisher, L. D. 1998. Self-designing clinical trials. Stat Med 17:1551-1562.
10. Friedman, L.; Furberg, C; and DeMets, D. 1998. Fundamentals of Clinical Trials. New York, New York: Springer-Verlag, 3rd edition.
11. Gilks, W. R. 1995. Markov Chain Monte Carlo in Practice. Chapman and Hall/CRC, 1 edition.
12. Haahr, M. T., and Hróbjartsson, A. 2006. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials 3(4):360-365.
13. Hellinger, E. 1909. Neue begründung der théorie quadratischer formen von unendlichvielen veränderlichen. Journal fur die reine und angewandte Mathematik 136:210-271.
14. Hróbjartsson, A.; Forfang, E.; Haahr, M. T.; Als-Ntelsen, B.; and Brorson, S. 2007. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol 36(3):654-663.
15. Hung, H. M. J.; Wang, S.-J.; and ONeill, R. T. 2006. Methodological issues with adaptation of clinical trial design. Pharmaceut Statist 5:99-107.
16. James, K. E.; Bloch, D. A.; Lee, K. K.; Kraemer, H. C; and Fuller, R. K. 1996. An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation-A va cooperative study. Stat Med 15(13): 1421-1434.
17. Jennison, C, and Turnbull, B. W. 2003. Mid-course sample size modification in clinical trials based on the observed treatment effect. Stat Med 22(6):971-993.
18. Kolahi, J.; Bang, H.; and Park, J. 2009. Towards a proposal for assessment of blinding success in clinical trials: up-to-date review. Community Dent Oral Epidemiol 37(6):477-484.
19. Kullback, S. Leibler, R. 1951. On information and sufficiency. Annals of Mathematical Statistics 22(1 ):79-86.
20. Lang, T. 2011. Adaptive trial design: Could we use this approach to improve clinical trials in the field of global health? Am J Trop Med Hyg 85(6):967-970.
21. Meinert, C. L. 1986. Clinical Trials: Design, Conduct, and Analysis. New York, New York: Oxford University Press, 3rd edition.
22. Nelson, N. J. 2010. Adaptive clinical trial design: Has its time come? JNCIJ Natl Cancer Inst 102(16): 1217-1218.
23. Nissen, S. E. 2006. ADAPT: The wrong way to stop a clinical trial. PLoS Clin Trials l(7):e35.
24. Penston, J. 2005. Large-scale randomised trials-A misguided approach to clinical research. Med Hypotheses 64(3):651-657.
25. Piantadosi, S. 1997. Clinical Trials: A Methodologie Per-spective. Hoboken, New Jersey: Wiley, 3rd edition.
26. Sackett, D. L. 2007. Commentary: Measuring the success of blinding in RCTs: don't, must, can't or needn't? Int J Epidemiol 36(3):664-665.
27. U.S. Department of Health and Human Services. 2010. Guidance for industry: Adaptive design clinical trials for drugs and biologies. Food and Drug Administration Draft Guidance.